FRIDAY, JUNE 22

3:00 p.m.-9:30 p.m.  Registration
Registration Desk B

6:00 p.m.-8:00 p.m.  Welcome and Opening Keynote Address
Salon E

6:00 p.m.-6:07 p.m.  Welcome from
AACR Chief Executive Officer
Margaret Foti, American Association for Cancer Research, Philadelphia, PA

6:07 p.m.-6:15 p.m.  Welcome from
Scientific Committee Chair
Ari M. Melnick, Weill Cornell Medical College, New York, NY

6:15 p.m.-6:45 p.m.  Keynote Address: Immunogenicity predicts prevention
Michael A. Caligiuri, City of Hope, Duarte, CA

6:45 p.m.-7:30 p.m.  Keynote Address: CAR T for lymphoma and beyond
Carl H. June, University of Pennsylvania, Philadelphia, PA

7:30 p.m.-8:00 p.m.  Panel discussion
Ari M. Melnick
Michael A. Caligiuri
Carl H. June

8:00 p.m.-10:00 p.m.  Opening Reception
Salon F
SATURDAY, JUNE 23

7:00 a.m.-8:00 a.m.  Breakfast
Salon F

7:15 a.m.-8:00 a.m.  Concurrent Sessions 1-2

Concurrent Session 1: Canine Lymphoma as a Surrogate for Human Lymphomas: What Can We Learn from Canine Clinical Trials?
Salons B-D

Session Co-chairs: Luca Aresu, University of Turin, Grugliasco, Italy, and Kristy L. Richards, Cornell University, Ithaca, NY

7:15 a.m.-8:00 a.m.  Panel discussion
Luca Aresu
Cheryl A. London, Tufts Medical Center, Boston, MA
Laura Marconato, Centro Oncologico Veterinario, Sasso Marconi, Italy
Kristy L. Richards

Concurrent Session 2: What Is the Optimal Therapeutic Approach to NHL in Adolescents and Young Adults: A Discussion from the Pediatric and Adult Perspectives
Salon E

Session Chair: Lisa G. Roth, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY

7:15 a.m.-8:00 a.m.  Panel discussion
Kieron Dunleavy, George Washington University, Washington, DC
Lisa G. Roth
8:00 a.m.-10:30 a.m.  **Plenary Session 1: Are We Ready for Lymphoma MATCH Trials?**  
Salon E  

**Session Chair:** Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY  

8:00 a.m.-8:25 a.m.  **Precision medicine based on the genetic taxonomy of DLBCL**  
Louis M. Staudt, National Cancer Institute, Bethesda, MD  

8:25 a.m.-8:50 a.m.  **How to design a MATCH trial for lymphoma**  
Anas Younes  

8:50 a.m.-9:15 a.m.  **Practical considerations for using genome sequencing data for patient selection**  
David W. Scott, BC Cancer Agency, Vancouver, BC, Canada  

9:15 a.m.-9:40 a.m.  **Molecular typing in DLBL: Subset and match?**  
Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom  

9:40 a.m.-9:55 a.m.  **Utilizing genomic sequencing from clinical assays in lymphoma management**  
Connie Batlevi, Memorial Sloan Kettering Cancer Center, New York, NY  

9:55 a.m.-10:30 a.m.  **Panel discussion**  
Connie Batlevi  
Peter W.M. Johnson  
David W. Scott  
Louis M. Staudt  
Anas Younes  

10:30 a.m.-11:00 a.m.  **Break**  
Salons A-E Foyer
11:00 a.m.-11:30 a.m. **Spotlight on Proffered Papers Session 1**  
(from posters in Session A)  
Salon E

11:00 a.m.-11:15 a.m. **Drugs in the curative RCHOP combination exhibit low cross-resistance but not pharmacologic synergy**  
Adam C. Palmer, Harvard Medical School, Boston, MA

11:15 a.m.-11:30 a.m. **MHC class II expression is associated with a distinct mutational profile and immune cell landscape of the microenvironment in GCB-DLBCL**  
Daisuke Ennishi, BC Cancer Agency, Vancouver, BC, Canada

11:45 a.m.-1:45 p.m. **Poster Session A / Lunch**  
Salon F

- Lymphoid Cancers 1
- Basic and Translational Science 1
- Other Topics
- Therapeutics and Clinical Trials in Lymphoma 1

2:00 p.m.-4:00 p.m. **Plenary Session 2: Targeting the Epigenome of DLBCL**  
Salon F

**Session Cochairs:** Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland, and Laura Pasqualucci, Columbia University Institute for Cancer Genetics, New York, NY

2:00 p.m.-2:25 p.m. **DNA and histone methylation as therapeutic targets in lymphoma**  
Ari M. Melnick, Weill Cornell Medical College, New York, NY
CONFERENCE SCHEDULE

Plenary Session 2 (cont’d)

2:25 p.m.-2:50 p.m.  **Targeting EZH2 in lymphoma**
Vincent Ribrag, Institut Gustave-Roussy, Villejuif, France

2:50 p.m.-3:15 p.m.  **Germinal center-derived lymphomas: At the intersection of genetics and epigenetics**
Laura Pasqualucci

3:15 p.m.-3:40 p.m.  **BET inhibitors in lymphoma**
Francesco Bertoni

3:30 p.m.-4:00 p.m.  **Panel discussion**
Francesco Bertoni
Ari M. Melnick
Laura Pasqualucci
Vincent Ribrag

4:00 p.m.-4:30 p.m.  **Break**
Salons A-E Foyer

4:30 p.m.-6:30 p.m.  **Plenary Session 3: Can Liquid Biopsies Replace Tissue and Be Used to Guide Clinical Decisions?**
Salon E

**Session Chair:** Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

4:30 p.m.-5:00 p.m.  **Circulating tumor DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies**
Constantine S. Tam, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
5:00 p.m.-5:30 p.m.  **Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?**  
Wyndham H. Wilson, National Cancer Institute, Bethesda, MD

5:30 p.m.-6:00 p.m.  **Use of circulating tumor DNA to genotype aggressive lymphomas**  
Davide Rossi

6:00 p.m.-6:30 p.m.  **Panel discussion**  
Lee M. Greenberger, The Leukemia & Lymphoma Society, Rye Brook, NY  
Davide Rossi  
Constantine S. Tam  
Wyndham H. Wilson

6:30 p.m.  **Dinner on own**

**SUNDAY, JUNE 24**

7:00 a.m.-8:00 a.m.  **Breakfast**  
Salon F

7:15 a.m.-8:00 a.m.  **Concurrent Sessions 3-4**

**Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?**  
Salons B-D

**Session Chair:** Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY
7:15 a.m.-7:30 a.m.  Using in vivo CRISPR-based screening to identify lymphoma drug targets
Michael T. Hemann, David H. Koch
Institute for Integrative Cancer Research at MIT, Cambridge, MA

7:30 a.m.-7:45 a.m.  Title to be announced
Sandeep S. Dave, Duke University, Durham, NC

7:45 a.m.-8:00 a.m.  Crispr-Cas9 screens interrogate lymphoma biology and lead to therapies
Hans-Guido Wendel

Concurrent Session 4: Genetic and Molecular Heterogeneity between Western and Asian Lymphoma Patients
Salon E

Session Chair: Wei-Li Zhao, Ruijin Hospital, Shanghai Institute of Hematology, Shanghai, China

7:15 a.m.-7:30 a.m.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma: Insights for novel targeted therapies
Qiang Pan-Hammarström, Karolinska Institute, Stockholm, Sweden

7:30 a.m.-7:45 a.m.  The genetics of marginal zone lymphomas
Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

7:45 a.m.-8:00 a.m.  Precise classification and treatment of NK/T and T-cell lymphoma
Wei-Li Zhao
8:00 a.m.-10:30 a.m.  **Plenary Session 4: Will CAR T Cells Replace BMT as a Modality for NHL?**  
Salon E

**Session Chair:** Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 a.m.-8:30 a.m. **Contemporary salvage therapy and autologous transplantation for relapsed and primary refractory DLBCL: The low bar has been firmly set**  
Craig S. Sauter, Memorial Sloan Kettering Cancer Center, New York, NY

8:30 a.m.-9:00 a.m. **Clinical overview of CAR T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: Promise and limitations**  
Michael R. Bishop, University of Chicago, Chicago, IL

9:00 a.m.-9:30 a.m. **Next-gen T cells**  
Renier J. Brentjens

9:30 a.m.-10:00 a.m. **CARS versus autos or CARS plus autos?**  
Stephen J. Forman, City of Hope, Duarte, CA

10:00 a.m.-10:30 a.m. **Panel discussion**  
Michael R. Bishop  
Renier J. Brentjens  
Stephen J. Forman  
Craig S. Sauter

10:30 a.m.-11:00 a.m. **Break**  
Salons A-E Foyer
11:00 a.m.-11:30 a.m. **Spotlight on Proffered Papers Session 2** (from posters in Session B) Salon E

11:00 a.m.-11:15 a.m. **Lenalidomide treatment restores in vivo T-cell activity in relapsed/refractory FL and DLBCL**
Cedric Menard, University of Rennes, Rennes, France

11:15 a.m.-11:30 a.m. **Anti-CD37 chimeric antigen receptor T cells: A new potential therapeutic option for non-Hodgkin lymphoma**
Irene Scarfo, Massachusetts General Hospital Cancer Center, Charlestown, MA

11:45 a.m.-1:45 p.m. **Poster Session B / Lunch**
Salon F
Therapeutics and Clinical Trials in Lymphoma 2
Lymphoid Cancers 2
Pathology and Classification of Lymphomas

2:00 p.m.-4:00 p.m. **Plenary Session 5: The Significance of Targeting the Microenvironment in Lymphoma**
Salon E

Session Chair: Karin Tarte, University of Rennes, Rennes, France

2:00 p.m.-2:30 p.m. **Ex vivo lymphoid tissue microenvironments to model epigenetics and signaling in healthy and malignant B cells**
Ankur Singh, Cornell University, Ithaca, NY
2:30 p.m.-3:00 p.m. Dissecting microenvironmental cues that promote B-cell lymphoma growth in secondary lymphoid organs
Uta E. Höpken, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

3:00 p.m.-3:30 p.m. Targeting cancer-associated fibroblasts to promote antitumor immunity
Hélène Salmon, Icahn School of Medicine at Mount Sinai, New York, NY

3:30 p.m.-4:00 p.m. Panel discussion
Uta E. Höpken
Hélène Salmon
Ankur Singh
Karin Tarte

4:00 p.m.-4:30 p.m. Break
Salons A-E Foyer

4:30 p.m.-6:30 p.m. Plenary Session 6: Follicular Lymphoma: When to Treat and How to Define Early Disease
Salon E

Session Chair: Bertrand Nadel, Centre d’Immunoologie de Marseille-Luminy, Marseille, France

4:30 p.m.-4:55 p.m. Committed precursor cells (CPC) and follicular lymphoma genesis
Bertrand Nadel

4:55 p.m.-5:20 p.m. Insights into early and late steps of follicular lymphoma pathogenesis from genomic studies
Robert Kridel, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
5:20 p.m.-5:45 p.m.  Clinical and biologic criteria for treatment decision in follicular lymphoma  
Gilles Salles, Lyon-Sud Charles Mérieux Medical School, Pierre Bénite, France

5:45 p.m.-6:10 p.m.  Front-line chemotherapy-free treatments for follicular lymphoma?  
Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

6:10 p.m.-6:30 p.m.  Panel discussion  
Robert Kridel  
Bertrand Nadel  
Gilles Salles  
Emanuele Zucca

6:30 p.m.  Dinner on own

MONDAY, JUNE 25

7:00 a.m.-8:00 a.m.  Breakfast  
Salon F

7:15 a.m.-8:00 a.m.  Concurrent Sessions 5-6

Concurrent Session 5: What Is the Molecular Basis and Most Promising Road towards Molecular Targeted Therapies for Double-Hit Lymphoma?  
Salons B-D

Session Chair: David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA
The laboratory challenge of double-hit lymphoma
David M. Weinstock

The clinical challenge of double-hit lymphoma
Philippe Armand, Dana-Farber Cancer Institute, Boston, MA

Panel discussion
Philippe Armand
David M. Weinstock

Concurrent Session 6: What Do Mutation Profiles Teach Us about Rare versus Common Forms of Lymphoma?
Salon E

Session Chair: Sandeep S. Dave, Duke University, Durham, NC

Rare vs. common: Using genomic discoveries for a unified view of lymphoma
Sandeep S. Dave

Pathways to clinical translation of genetic discoveries
Eric D. Hsi, The Cleveland Clinic, Cleveland, OH

Panel discussion
Sandeep S. Dave
Eric D. Hsi
8:00 a.m.-10:30 a.m.  **Plenary Session 7: How Do Clonal Dynamics and Tumor Heterogeneity Factor into Clinical Outcome and Therapy?**  
Salon E  

**Session Chair:** Dan A. Landau, Weill Cornell Medical College, New York, NY  

8:00 a.m.-8:30 a.m.  **3'-UTR disruption of PD-L1 in malignant lymphomas**  
Seishi Ogawa, Kyoto University Graduate School of Medicine, Kyoto, Japan  

8:30 a.m.-9:00 a.m.  **Actionable molecular heterogeneity in DLBCL**  
Bjoern Chapuy, Dana-Farber Cancer Institute, Boston, MA  

9:00 a.m.-9:30 a.m.  **Epigenetic determinants of normal and malignant somatic evolution**  
Dan A. Landau  

9:30 a.m.-9:45 a.m.  **Ibrutinib does not suppress clonal evolution in high-risk chronic lymphocytic leukemia**  
Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland  

9:45 a.m.-10:00 a.m.  **Genetic landscape of extranodal marginal zone (MALT) lymphomas**  
Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland  

10:00 a.m.-10:30 a.m.  **Panel discussion**  
Francesco Bertoni  
Bjoern Chapuy  
Dan A. Landau  
Seishi Ogawa  
Davide Rossi
10:30 a.m.-11:00 a.m. **Break**
Salons A-E Foyer

11:00 a.m.-11:30 a.m. **Spotlight on Proffered Papers Session 3**
(from posters in Session C)
Salon E

11:00 a.m.-11:15 a.m. **HSF1 orchestrates a prolymphomagenic microenvironment through matrix remodeling and deficient lymphoma immunity**
Jude M. Phillip, Weill Cornell Medicine, New York, NY

11:15 a.m.-11:30 a.m. **The ETS inhibitors YK-4-279 and TK-216 synergize with lenalidomide via SPIB downregulation in diffuse large B-cell lymphoma of the activated B cell-like type (ABC DLBCL)**
Filippo Spriano, Institute of Oncology Research, Bellinzona, Switzerland

11:45 a.m.-1:45 p.m. **Poster Session C / Lunch**
Salon F
Basic and Translational Science 2
Diagnostic and Prognostic Biomarkers
Ethnicity as a Risk Factor in Cancer Disparities
Therapeutics and Clinical Trials in Lymphoma 3
2:00 p.m.-4:00 p.m.  **Plenary Session 8: What Is the Role for Checkpoint Protein Functionality and Therapeutic Blockade in Lymphoma?**
Salon E

**Session Chair:** Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

2:00 p.m.-2:30 p.m.  **Exploiting epigenetic and immune vulnerabilities in lymphoma**
Ricky W. Johnstone, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

2:30 p.m.-3:00 p.m.  **Targetable genetic bases of immune evasion in lymphoma**
Margaret A. Shipp

3:00 p.m.-3:30 p.m.  **In situ vaccination for lymphoma**
Ronald Levy, Stanford University, Stanford, CA

3:30 p.m.-4:00 p.m.  **Panel discussion**
Ronald Levy
Margaret A. Shipp

4:00 p.m.-4:30 p.m.  **Break**
Salons A-E Foyer

4:30 p.m.-6:30 p.m.  **Plenary Session 9: How Can We Improve the Outcome of Patients with PTCL?**
Salon E

**Session Chair:** Kerry Savage, University of British Columbia, Vancouver, BC, Canada

4:30 p.m.-4:55 p.m.  **How do we raise the therapeutic bar in PTCLs?**
Kerry Savage

4:55 p.m.-5:20 p.m.  **Genomics and pathobiology of PTCL**
Wing C. Chan, City of Hope, Duarte, CA
5:20 p.m.-5:45 p.m.  **PDX models in T-cell lymphoma**  
David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA

5:45 p.m.-6:00 p.m.  **Novel drug combinations**  
Neha Mehta-Shah, Washington University Medical School, St. Louis, MO

6:00 p.m.-6:30 p.m.  **Panel discussion**  
Wing C. Chan  
Neha Mehta-Shah  
Kerry Savage  
David M. Weinstock

6:30 p.m.  **Dinner on own**

**TUESDAY, JUNE 26**

7:00 a.m.-8:00 a.m.  **Breakfast**  
Salons B-D

8:00 a.m.-10:00 a.m.  **Keynote Lectures**  
Salon E

8:00 a.m.-8:45 a.m.  **Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures**  
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

8:45 a.m.-9:30 a.m.  **Targeting Achilles heels in multiple myeloma**  
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
9:30 a.m.-10:00 a.m.  Panel discussion  
James P. Allison  
Kenneth C. Anderson  
Ari M. Melnick

10:00 a.m.-10:15 a.m.  Break  
Salons A-E Foyer

10:15 a.m.-12:15 p.m.  Plenary Session 10:  
Transforming First-Line Therapy for Hodgkin and Non-Hodgkin Lymphoma  
Salon E

Session Chair: Thomas E. Witzig, Mayo Clinic College of Medicine, Rochester, MN

10:15 a.m.-10:45 a.m.  Standard of care in 2018 for DLBCL: Setting the stage for the next NCTN trials  
Thomas E. Witzig

10:45 a.m.-11:15 a.m.  Transforming the front-line care of PTCL  
Owen A. O'Connor, Columbia University Medical Center, New York, NY

11:15 a.m.-11:45 a.m.  Title to be announced  
Kerry Savage, University of British Columbia, Vancouver, BC, Canada

11:45 a.m.-12:15 p.m.  Panel discussion  
Owen A. O’Connor  
Kerry Savage  
Thomas E. Witzig

12:15 p.m.-12:30 p.m.  Meeting Highlights: Promise for the Future  
Salon E

Ari M. Melnick, Weill Cornell Medical College, New York, NY